Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Soligenix, Inc.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 7: Clinical Trial Trends
From synthetic data to real-world data, from patient engagement to patient stratification, from combination trials to master protocols and from fully decentralized through hybrid to onsite trials, the world of clinical development is undergoing major changes. Fifty executives share their predictions around clinical trial trends for the year ahead.
Private Equity Firm Yellow Wood Plans Refresh For Suave Beauty, Hair Products In US, Canada
Suave hair and beauty brand getting new home in US and Canada at private equity firm Yellow Wood Partners, which plans to grow line through innovation, marketing and distribution. Unilever maintains ownership in other regions.
Keeping Track: Travere’s Filspari, Chiesi’s Lamzede, Apellis’ Syfovre Headline US FDA Approvals; CRLs For Phathom, Biocon
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
HBW Market Executive Decisions: Unilever’s Next CEO, CRN Staff, GOED Board, PLZ CEO
Unilever names Schumacher as Jope’s successor at CEO; specialty aerosol, liquid products firm PLZ appoints CEO; GOED seats 2023 board officers; and CRN adds and promotes staff members.
- Drug Delivery
- Large Molecule
- Other Names / Subsidiaries
- Biological Therapeutics, Inc.
- DOR BioPharma, Inc.
- Endorex Corporation
- Enteron Pharmaceuticals
- Immunotherapeutics Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.